Ryser MD, Lange J, Inoue LYT, O'Meara ES, Gard C, Miglioretti DL, Bulliard JL, Brouwer AF, Hwang ES, Etzioni R. Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. Ann Intern Med. 2022;10.7326/M21-3577.
Coles CE, Anderson BO, Cameron D, Cardoso F, Horton R, Knaul FM, Mutebi M, Lee N; Lancet Breast Cancer Commission (including Etzioni R). The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge. Lancet. 2022;399(10330):1101-1103
Jiao B, Gulati R, Katki HA, Castle PE, Etzioni R. A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. Cancer Epidemiol Biomarkers Prev. 2022;31(1):38-44.
Etzioni R, Gulati R, Weiss NS. Multi-cancer early detection: Learning from the past to meet the future. J Natl Cancer Inst. 2022;114(3):349-352
Etzioni R, Haffner MC, Gulati R. Divining harm-benefit tradeoffs of magnetic resonance imaging-targeted biopsy. Eur Urol. 2021 Aug 31:S0302-2838(21)01977-1.
Zelner J, Riou J, Etzioni R, Gelman A. Accounting for uncertainty during a pandemic. Patterns (N Y). 2021 Aug 13;2(8):100310.
Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, Etzioni R. Economic evaluation of urine-based or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States. Value Health. 2021 Aug;24(8):1111-1117.
Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. Clarifying the trade-offs of risk-stratified screening for prostate cancer: A cost-effectiveness study. Am J Epidemiol. 2021 May 22:kwab155.
Gulati R, Carlsson SV, Etzioni R. When to discuss prostate cancer screening with average-risk men. Am J Prev Med. 2021 Aug;61(2):294-298.
Nyame YA, Gulati R, Heijnsdijk EAM, Tsodikov A, Mariotto AB, Gore JL, Etzioni R. The impact of intensifying prostate cancer screening in Black men: A model-based analysis. J Natl Cancer Inst. 2021 May 8:djab072.
Gogebakan KC, Mukherjee K, Berry EG, Sonmez K, Leachman SA, Etzioni R. Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. Cancer. 2021 Aug 15;127(16):2926-2933.
Beatty JD, Sun Q, Markowitz D, Chubak J, Huang B, Etzioni R. Identifying breast cancer recurrence histories via patient-reported outcomes. J Cancer Surviv. 2021 Apr 14.
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426.
Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021 Mar 3;12(1):1426.
Lange J, Remmers S, Gulati R, Bill-Axelson A, Johansson JE, Kwiatkowski M, Auvinen A, Hugosson J, Hu JC, Roobol MJ, Carlsson SV, Etzioni R. Impact of cancer screening on metastasis: A prostate cancer case study. J Med Screen. 2021 Feb 9:969141321989738.
Shih YT, Dong W, Xu Y, Etzioni R, Shen Y. Incorporating baseline breast density when screening women at average risk for breast cancer: A cost-effectiveness analysis. Ann Intern Med. 2021 May;174(5):602-612.
Aleshin-Guendel S, Lange J, Goodman P, Weiss NS, Etzioni R. A latent disease model to reduce detection bias in cancer risk prediction studies. Eval Health Prof. 2021 Mar;44(1):42-49.
Nyame YA, Gulati R, Tsodikov A, Gore JL, Etzioni R. Prostate-specific antigen screening and recent increases in advanced prostate cancer. JNCI Cancer Spectr. 2020 Oct 26;5(1):pkaa098.
Etzioni R, Shen Y, Shih YT. Identifying preferred breast cancer risk predictors: A holistic perspective. J Natl Cancer Inst. 2020 Dec 10:djaa181.
Etzioni R, Nyame YA. Prostate cancer screening guidelines for black men: Spotlight on an empty stage. J Natl Cancer Inst. 2020 Nov 4:djaa172.
Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLoS One. 2020 Sep 30;15(9):e0239686.
Gogebakan KC, Berry EG, Geller AC, Sonmez K, Leachman SA, Etzioni R. Strategizing screening for melanoma in an era of novel treatments: A model-based approach. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2599-2607.
A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R. Incorporating breast cancer recurrence events into population-based cancer registries using medical claims: Cohort study. JMIR Cancer. 2020 Aug 17;6(2):e18143.
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, Guerra CE, Oeffinger KC, Shih YT, Walter LC, Kim JJ, Andrews KS, DeSantis CE, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC, Smith RA. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020 Sep;70(5):321-346.
Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade. JCO Precis Oncol. 2020;4:382-392.
Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020 Jun 18;382(25):2465-2468.
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020 May 26;31(8):107669.
Fudim M, Dalgaard F, Al-Khatib SM, J Friedman D, Lallinger K, Abraham WT, Cleland JGF, Curtis AB, Gold MR, Kutyifa V, Linde C, Schaber DE, Tang A, Ali- Ahmed F, Goldstein SA, Kaufman B, Fortman R, Davis JK, Inoue LYT, Sanders GD. Future research prioritization in cardiac resynchronization therapy. Am Heart J. 2020 May;223:48-58.
Heijnsdijk EAM, Gulati R, Tsodikov A, Lange JM, Mariotto AB, Vickers AJ, Carlsson SV, Etzioni R. Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer. J Natl Cancer Inst. 2020 Oct 1;112(10):1013-1020.
Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Identification of therapeutic vulnerabilities in small-cell neuroendocrine prostate cancer. Clin Cancer Res. 2020 Apr 1;26(7):1667-1677.
Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. 2020 Feb 1;126(3):583-592.
Patel NA, Sedrakyan A, Bianco F, Etzioni R, Gorin MA, Hsu WC, Mao J, Nguyen PL, Schaeffer E, Shoag J, Vickers A, Hu JC. Definitive and sustained increase in prostate cancer metastases in the United States. Urol Oncol. 2019 Dec;37(12):988-990.
Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. Durable response of enzalutamide-resistant prostate cancer to supraphysiological testosterone is associated with a multifaceted growth suppression and impaired DNA damage response transcriptomic program in patient-derived xenografts. Eur Urol. 2020 Feb;77(2):144-155.
Gulati R, Morgan TM, A'mar T, Psutka SP, Tosoian JJ, Etzioni R. Overdiagnosis and lives saved due to reflex testing men with intermediate prostate-specific antigen levels. J Natl Cancer Inst. 2019 Jun 21.
Gulati R, Psutka SP, Etzioni R. Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication. J Urol. 2019 May 21.
Schenk JM, Neuhouser ML, Beatty SJ, VanDoren M, Lin DW, Porter M, Gore JL, Gulati R, Plymate SR, Wright JL. Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Contemp Clin Trials. 2019 Jun;81:34-39.
Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate. 2019 May;79(7):701-708.
Karlsson A, Jauhiainen A, Gulati R, Eklund M, Grönberg H, Etzioni R, Clements M. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. PLoS One. 2019 Feb 14;14(2):e0211918.
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Etzioni R, Hyslop T, Lee SJ, Hwang ES. Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst. 2019 Feb 13.
Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. Estimating and comparing cancer progression risks under varying surveillance protocols. Ann Appl Stat. 2018 Sep;12(3):1773-1795.
Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R. Can we use survival data from cancer registries to learn about disease recurrence? The case of breast cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1332-1341.
Ryser MD, Gulati R, Eisenberg MC, Shen Y, Hwang ES, Etzioni RB. Identification of the fraction of indolent tumors and associated overdiagnosis in breast cancer screening trials. Am J Epidemiol. 2019 Jan 1;188(1):197-205.
Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: A modelling study. Lancet Glob Health. 2018 Aug;6(8):e885-e893.
Lim DM, Gulati R, Aleshin-Guendel S, Gawne A, Wingate JT, Cheng HH, Etzioni R, Yu EY. Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate. 2018 Jul 10.
Odisho AY, Etzioni R, Gore JL. Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery. Cancer. 2018 Jun 15.
Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One. 2018 Jun 1;13(6):e0198389.
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018 May 30.
Tsodikov A, Gulati R, Etzioni R. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2018 Apr 17;168(8):608-609.
Etzioni R, Gulati R. When clinical trials disagree. J Urol. 2018 Mar 1.
Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes. Eur Urol. 2018 Feb 9.
Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R. Estimating the frequency of indolent breast cancer in screening trials. Stat Methods Med Res. 2018 Jan 1:962280217754232.
Kaur D, Ulloa-Pérez E, Gulati R, Etzioni R. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. Cancer. 2018 Apr 15;124(8):1752-1759.
de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. 2018 Mar 15;124(6):1197-1206.
Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative analysis of biopsy upgrading in four prostate cancer active surveillance cohorts. Ann Intern Med. 2018 Jan 2;168(1):1-9.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY; RISC Investigators. Venous thromboembolism risk in patients with locoregional urothelial tract tumors. Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30242-2.
Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017 Oct 3;167(7):449-455.
Lange JM, Trock BJ, Gulati R, Etzioni R. A framework for treatment decision making at prostate cancer recurrence. Med Decis Making. 2017 Nov;37(8):905-913.
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815.
Lawless M, Gulati R, Tretiakova M. Stalk versus base invasion in pT1 papillary cancers of the bladder: Improved substaging system predicting risk of progression. Histopathology. 2017 May 4.
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R. Is prostate cancer different in black men? answers from 3 natural history models. Cancer. 2017 Apr 24.
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery B. Association of tissue abiraterone levels and SLCO genotype with intraprostatic steroids and pathologic response in men with high-risk localized prostate cancer. Clin Cancer Res. 2017 Apr 7.
Duffy SW, Etzioni R, Sasieni P. Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evid Based Med. 2017 Apr;22(2):76.
Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res. 2017 May 1;23(9):2301-2312.
Gulati R, Albertsen PC. Insights from the PLCO trial about prostate cancer screening. Cancer. 2017 Feb 15;123(4):546-548.
Lee CI, Etzioni R. Missteps in current estimates of cancer overdiagnosis. Acad Radiol. 2017 Feb;24(2):226-229.
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget. 2016 Jun 28;7(26):40690-40703.
Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227.
Loggers ET, Buist DS, Gold LS, Zeliadt S, Hunter Merrill R, Etzioni R, Ramsey SD, Sullivan SD, Kessler L. Advanced imaging and receipt of guideline concordant care in women with early stage breast cancer. Int J Breast Cancer. 2016;2016:2182985.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016 Aug 4;375(5):443-53.
Gulati R, Feuer EJ, Etzioni R. Conditions for valid empirical estimates of cancer overdiagnosis in randomized trials and population studies. Am J Epidemiol. 2016 Jul 15;184(2):140-7.
Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Med Oncol. 2016 Jul;33(7):77.
Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M. A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer. Prostate. 2016 Oct;76(14):1285-92.
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN guidelines insights: Prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw. 2016 May;14(5):509-19.
Gulati R, Etzioni R. A matched cohort analysis of prostate cancer screening in younger men in Sweden. Eur Urol. 2017 Jan;71(1):53-54.
Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. 2016 Jul 1;2(7):890-8.
Etzioni R, Gulati R. Recent trends in PSA testing and prostate cancer incidence: A look at context. JAMA Oncol. 2016 Jul 1;2(7):955-6.
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016 Apr;22(4):369-78.
Wingate JT, Etzioni R, Macdonald DM, Brand TC. Treatment trends for stage I testicular seminoma in an equal-access medical system. Clin Genitourin Cancer. 2016 Oct;14(5):438-443.
Birnbaum J, Gadi VK, Markowitz E, Etzioni R. The effect of treatment advances on the mortality results of breast cancer screening trials: A microsimulation model. Ann Intern Med. 2016 Feb 16;164(4):236-43.
Etzioni R, Gulati R. Active surveillance for ductal carcinoma in situ: Shining light into the modeling abyss. J Natl Cancer Inst. 2015 Dec 17;108(5).
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN clinical practice guidelines prostate cancer early detection, version 2.2015. J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61.
Etzioni R, Gulati R. Recognizing the limitations of cancer overdiagnosis studies: A first step towards overcoming them. J Natl Cancer Inst. 2015 Nov 18;108(3).
Birnbaum JK, Ademuyiwa FO, Carlson JJ, Mallinger L, Mason MW, Etzioni R. Comparative effectiveness of biomarkers to target cancer treatment: Modeling implications for survival and costs. Med Decis Making. 2016 Jul;36(5):594-603.
Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R; American Cancer Society.. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614.
Etzioni R, Gulati R. Active surveillance for ductal carcinoma in situ: Shining light into the modeling abyss. J Natl Cancer Inst. 2015 Dec 17;108(5).
Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM Jr, Lucia MS, Kristal AR. Difference in association of obesity with prostate cancer risk between US African American and non-hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol. 2015 Jun;1(3):342-9.
Elmore JG, Etzioni R. Effect of screening mammography on cancer incidence and mortality. JAMA Intern Med. 2015 Sep;175(9):1490-1.
Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, Buist DS; ADVICE Investigators. Predictors of preoperative MRI for breast cancer: Differences by data source. J Comp Eff Res. 2015 May 11:1-12.
Jeldres C, Cullen J, Hurwitz LM, Wolff EM, Levie KE, Odem-Davis K, Johnston RB, Pham KN, Rosner IL, Brand TC, L'Esperance JO, Sterbis JR, Etzioni R, Porter CR. Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer. 2015 Jul 15;121(14):2465-73.
Habbema JD, Wilt TJ, Etzioni R. Models in the development of clinical practice guidelines. Ann Intern Med. 2015 Apr 7;162(7):530-1.
Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS, Nelson PS, Wagner AA, Wei JT, Etzioni R, Lin DW. Precision medicine in active surveillance for prostate cancer: Development of the Canary-Early Detection Research Network active surveillance biopsy risk calculator. Eur Urol. 2015 Dec;68(6):1083-8.
Etzioni R, Gulati R, Lin DW. Measures of survival benefit in cancer drug development and their limitations. Urol Oncol. 2015 Mar;33(3):122-7.
Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R. Projecting benefits and harms of novel cancer screening biomarkers: A study of PCA3 and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):677-82.
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7.
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. J Natl Cancer Inst. 2014 Dec 24;107(2).
Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R. A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst. 2014 Oct 31;106(12).
Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. PLoS One. 2014 Oct 30;9(10):e111545.
Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol. 2015 Jan 10;33(2):149-55.
Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: Estimates based on patient and tumor characteristics. Clin Cancer Res. 2014 Oct 15;20(20):5302-10.
Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014 Nov 15;120(22):3519-26.
Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget. 2014 Oct 30;5(20):9939-51.
Weiner AB, Etzioni R, Eggener SE. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct;66(4):611-2.
Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9.
Etzioni R, Gulati R. Oversimplifying overdiagnosis. J Gen Intern Med. 2014 Sep;29(9):1218-20.
Etzioni R. Impact of prostate-specific antigen screening: Building confidence. Eur Urol. 2014 Sep;66(3):404-5.
Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer. 2014 Aug 15;135(4):939-47.
Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, Yu EY. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer. 2014 Aug 10.
Weiner AB, Patel SG, Etzioni R, Eggener SE. National trends in the management of low- and intermediate-risk prostate cancer in the United States. J Urol. 2014 Aug 5.
Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS. Personalizing age of cancer screening cessation based on comorbid conditions: Model estimates of harms and benefits. Ann Intern Med. 2014 Jul 15;161(2):104-12.
Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: A modeling study. Ann Intern Med. 2014 May 6;160(9):594-602.
Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? Urol Clin North Am. 2014 May;41(2):223-8.
Etzioni R, Gulati R. RE: A model too far. J Natl Cancer Inst. 2014 Apr;106(4):dju058.
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Stat Med. 2014 Mar 15;33(6):930-9.
Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014 Mar;106(3):dju002.
Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst. 2014 Feb;106(2):djt367.
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: A pilot study. J Clin Oncol. 2014 Jan 20;32(3):229-37.
Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One. 2014;9(9):e104271.
Ayala G, Frolov A, Ittman M, Mohammed S, LeBlanc M, Falcon S, Rowley D, Etzioni R. Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort. Ann Clin Lab Sci. 2013 Winter;43(1):11-21.
Gold LS, Buist DS, Loggers ET, Etzioni R, Kessler L, Ramsey SD, Sullivan SD. Advanced diagnostic breast cancer imaging: Variation and patterns of care in Washington State. J Oncol Pract. 2013 Sep;9(5):e194-202.
Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol. 2013 Sep 1;178(5)741-51.
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early Detection of prostate cancer: AUA guideline. J Urol. 2013 Aug;190(2):419-26.
Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013 Jun 4;158(11):831-8.
Gulati R, Etzioni R. Alternative prostate cancer screening strategies--in response. Ann Intern Med. 2013 May 21;158(10):778-9.
Etzioni R, Gulati R. Response: Reading between the lines of cancer screening trials: Using modeling to understand the evidence. Med Care. 2013 Apr;51(4):304-6.
Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, Walter L, Wolf AM, Brawley OW, Smith RA. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17.
Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R. Effects of screening on radical prostatectomy efficacy: The prostate cancer intervention versus observation trial. J Natl Cancer Inst. 2013 Apr 17;105(8):546-50.
Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and prostate cancer screening. Med Care. 2013 Apr;51(4):295-300.
Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B, Nelson PS, Vessella RL, Morrissey C. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol. 2013 Feb 16;14:6.
Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: Model estimates of potential benefits and harms. Ann Intern Med. 2013 Feb 5;158(3):145-53.
Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I. Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. J Natl Cancer Inst Monogr. 2013;2013(46):117-23.
Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res. 2012 Oct 1;18(19):5471-8.
Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res. 2012 Dec 15;18(24):6742-7.
Etzioni RD. Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development. Evid Based Med. 2013 Apr;18(2):75-6.
Inoue LY, Gulati R, Yu C, Kattan MW, Etzioni R. Deriving benefit of early detection from biomarker-based prognostic models. Biostatistics. 2013 Jan;14(1):15-27.
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines. Cancer. 2012 Dec 1;118(23):5955-63.
Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2012 May 20;30(15):1864-70.
Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control. 2012 Jun;23(6):827-35.
Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med. 2012 Jan;42(1):37-43.
Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol. 2011 Dec;64(12):1412-7.
Lewinshtein D, Gulati R, Nelson PS, Porter CR. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int. 2012 Mar;109(5):706-12.
Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R. What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):740-50.
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, O'Brien D, Hopkins SE, Stephensen CB, Stanhope KL, Havel PJ, Boyer B. Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. Eur J Clin Nutr. 2011 Jul;65(7):808-17.
Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011 Mar 16;103(6):520-3.
Ramsey SD, Etzioni R. Case-control studies of cancer surveillance procedures. J Clin Epidemiol. 2011 Jan;64(1):44.
Fedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2437-44.
Zeliadt SB, Hoffman RM, Etzioni R, Ginger VA, Lin DW. What happens after an elevated PSA test: The experience of 13,591 veterans. J Gen Intern Med. 2010 Nov;25(11):1205-10.
Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: A critical precursor to policy development in cancer control. Biostatistics. 2010 Oct;11(4):707-19.
Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010 Jun 1;28(16):2668-73.
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98.
Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R, Wei JT. NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb;8(2):240-62.
Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 2010 Apr;21(4):423-32.
Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, Boyer B, Mohatt GV. Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr. 2010 Mar;91(3):777-85.
Shaw PA, Pepe MS, Alonzo TA, Etzioni R. Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Stat Biopharm Res. 2009 Feb 1;1(1):18-25.
Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate. 2010 Mar 1;70(4):412-24.
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst. 2009 Mar 18;101(6):374-83.
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R. Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):808-15.
Telesca D, Inoue LY, Neira M, Etzioni R, Gleave M, Nelson C. Differential expression and network inferences through functional data modeling. Biometrics. 2009 Sep;65(3):793-804.
Thompson IM, Ankerst DP, Etzioni R, Wang T. It's time to abandon an upper limit of normal for prostate specific antigen: Assessing the risk of prostate cancer. J Urol. 2008 Oct;180(4):1219-22.
Etzioni R, Feuer E. Studies of prostate-cancer mortality: Caution advised. Lancet Oncol. 2008 May;9(5):407-9.
Etzioni R. Statistical issues in the evaluation of screening and early detection modalities. Urol Oncol. 2008 May-Jun;26(3):308-15.
Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach. Med Decis Making. 2008 May-Jun;28(3):323-31.
Inoue LYT, Etzioni R, Morrell C, Muller P. Modeling disease progression with longitudinal markers. J Am Stat Assoc. 2008 Mar;103(481):259-270.
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008 Mar;19(2):175-81.
Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst. 2007 Oct 17;99(20):1510-5.
Kawachi MH, Bahnson RR, Barry M, Carroll PR, Carter HB, Catalona WJ, Epstein JI, Etzioni RB, Hemstreet GP 3rd, Howe RJ, Kopin JD, Lange PH, Lilja H, Mohler J, Moul J, Nadler RB, Patterson S, Pollack A, Presti JC, Stroup AM, Urban DA, Wake R, Wei JT; National Comprehensive Cancer Network. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug;5(7):714-36.
Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008 Mar;64(1):10-9.
Ramsey SD, Howlader N, Etzioni R, Brown ML, Warren JL, Newcomb P. Surveillance endoscopy does not improve survival for patients with local and regional stage colorectal cancer. Cancer. 2007 Jun 1;109(11):2222-8.
Etzioni RD, Ankerst DP, Thompson IM. Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2007 Mar 21;99(6):489-90; author reply 490.
Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007 May 1;109(9):1877-86.
Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: The healthy screenee effect. Med Care. 2007 Feb;45(2):154-9.
DeConde RP, Hawley S, Falcon S, Clegg N, Knudsen B, Etzioni R. Combining results of microarray experiments: A rank aggregation approach. Stat Appl Genet Mol Biol. 2006;5:Article15.
Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics. 2007 Jul;8(3):507-25.
Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):395-402.
Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006 Jan 15;106(2):320-8.
Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: Results from the prostate cancer prevention trial. J Urol. 2005 Sep;174(3):877-81. Erratum in: J Urol. 2005 Nov;174(5):2071.
Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med. 2005 Aug;118(8):850-7.
Zeliadt SB, Etzioni R, Kristal AR. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer. 2005 Oct 1;104(7):1556-7; author reply 1557.
Etzioni R, Hawley S, Billheimer D, True LD, Knudsen B. Analyzing patterns of staining in immunohistochemical studies: Application to a study of prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1040-6.
Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L, Etzioni R, Ostrander EA, Stanford JL. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate. 2005 Sep 15;65(1):44-51.
Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol. 2004 Dec 15;22(24):4971-8.
Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. Int J Cancer. 2005 Apr 20;114(4):563-71.
Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004 Dec;64(6):1171-6.
Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: Examples from mammography and PSA testing. Stat Methods Med Res. 2004 Dec;13(6):421-42.
Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004 Dec 1;160(11):1059-69.
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology. 2004 Oct;64(4):814-20.
Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: Do combination tests improve detection? Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1640-5.
Etzioni R, Thomas DB. Modelling the effect of screening for cervical cancer on the population. Lancet. 2004 Jul 17-23;364(9430):224-6.
Weiss NS, Dhillon PK, Etzioni R. Case-control studies of the efficacy of cancer screening: Overcoming bias from nonrandom patterns of screening. Epidemiology. 2004 Jul;15(4):409-13.
Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF. Combining longitudinal studies of PSA. Biostatistics. 2004 Jul;5(3):483-500.
Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology. 2003 Dec;125(6):1645-50.
Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1410-6.
Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics. 2003 Oct;4(4):523-38.
Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer. 2003 Aug 1;98(3):496-503.
Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National Emphysema Treatment Trial Research Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med. 2003 May 22;348(21):2092-102.
Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int J Cancer. 2003 Jul 1;105(4):480-3.
Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer. 2003 Apr;3(4):243-52.
Weiss NS, Etzioni R. Estimating the influence of rescreening interval on the benefits associated with cancer screening: Approaches and limitations. Epidemiology. 2002 Nov;13(6):713-7.
Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1033-40.
Kessler LG, Andersen MR, Etzioni R. Much ado about mammography variability. J Natl Cancer Inst. 2002 Sep 18;94(18):1346-7.
Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002 Aug;40(8 Suppl):IV-104-17.
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.
Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: Administrative claims data, clinical trials, and beyond. Med Care. 2002 Jun;40(6 Suppl):III63-72.
Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol. 2002 Feb;97(2):440-5.
Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: An analysis of Medicare claims from 1991-1998. Urology. 2002 Feb;59(2):251-5.
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001 Oct 16;135(8 Pt 1):577-88.
Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61.
Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J Urol. 2001 Jul;166(1):93-8; discussion 98-9.
Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: A colorectal cancer case study. Health Econ. 2001 Apr;10(3):245-56.
Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am. 2000 Aug;14(4):925-38.
Andersen MR, Yasui Y, Meischke H, Kuniyuki A, Etzioni R, Urban N. The effectiveness of mammography promotion by volunteers in rural communities. Am J Prev Med. 2000 Apr;18(3):199-207.
Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma. Cancer. 2000 Mar 15;88(6):1294-303.
Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: Application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999 Dec;37(12):1249-59.
Feinstein LC, Seidel K, Jocum J, Bowden RA, Anasetti C, Deeg HJ, Flowers ME, Kansu E, Martin PJ, Nash RA, Storek J, Etzioni R, Applebaum FR, Hansen JA, Storb R, Sullivan KM. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5(6):369-78.
Etzioni RD, Feuer EJ, Sullivan SD, Lin D, Hu C, Ramsey SD. On the use of survival analysis techniques to estimate medical care costs. J Health Econ. 1999 Jun;18(3):365-80.
Andersen MR, Urban N, Etzioni R. Community attitudes and mammography use: Does it really matter what other people think? Women Health. 1999;29(3):83-95.
Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies. J Urol. 1999 Sep;162(3 Pt 1):741-8.
Etzioni R, Pepe M, Longton G, Hu C, Goodman G. Incorporating the time dimension in receiver operating characteristic curves: A case study of prostate cancer. Med Decis Making. 1999 Jul-Sep;19(3):242-51.
Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: Interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999 Jun 16;91(12):1033-9.
Cronin KA, Legler JM, Etzioni RD. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Stat Med. 1998 Nov 15;17(21):2509-23.
Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998 Oct 15;148(8):775-85.
Etzioni RD, Weiss NS. Analysis of case-control studies of screening: Impact of misspecifying the duration of detectable preclinical pathologic changes. Am J Epidemiol. 1998 Aug 1;148(3):292-7.
Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 1997 Jun;18(3):251-70.
Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997 Jun;53(2):419-34.
Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: The AIDS connection. Stat Med. 1997 Mar 30;16(6):627-44.
Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology. 1996 Jun;47(6):863-9.
Etzioni R, Thompson IM. Prostate cancer and computer models: Background, limitations, and potential. Urol Oncol. 1996 Mar-Apr;2(2):57-64.
Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: A reassessment. Prostate Suppl. 1996;7:70-7.
Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996 Jan;49(1):95-103.
Urban N, Taplin SH, Taylor VM, Peacock S, Anderson G, Conrad D, Etzioni R, White E, Montano DE, Mahloch J, et al. Community organization to promote breast cancer screening among women ages 50-75. Prev Med. 1995 Sep;24(5):477-84.
Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum FR, Doney K, Martin P, Slattery J, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood. 1995 Jun 15;85(12):3746-53.
Self SG, Etzioni R. A likelihood ratio test for cancer screening trials. Biometrics. 1995 Mar;51(1):44-50.
Etzioni R, Self SG. On the catch-up time method for analyzing cancer screening trials. Biometrics. 1995 Mar;51(1):31-43. Erratum in: Biometrics 1995 Dec;51(4):1589.
Etzioni RD, Connor RJ, Porok PC, Self SG. Design and analysis of cancer screening trials. Stat Methods Med Res. 1995 Mar;4(1):3-17.
Etzioni RD, Kadane JB. Bayesian statistical methods in public health and medicine. Annu Rev Public Health. 1995;16:23-41.
Anasetti C, Etzioni R, Petersdorf EW, Martin PJ, Hansen JA. Marrow transplantation from unrelated volunteer donors. Annu Rev Med. 1995;46:169-79.
Etzioni R, Pepe MS. Monitoring of a pilot toxicity study with two adverse outcomes. Stat Med. 1994 Nov 30;13(22):2311-21.
Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, Bryant E, Clift R, Deeg HJ, Doney K, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994 Aug 1;84(3):941-9.
Mickelson EM, Guthrie LA, Etzioni R, Anasetti C, Martin PJ, Hansen JA. Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. Tissue Antigens. 1994 Aug;44(2):83-92.
Etzioni RD, Fienberg SE, Gilula Z, Haberman SJ. Statistical models for the analysis of ordered categorical data in public health and medical research. Stat Methods Med Res. 1994;3(2):179-204.
Ritchey ML, Kelalis PP, Etzioni R, Breslow N, Shochat S, Haase GM. Small bowel obstruction after nephrectomy for Wilms' tumor. A report of the National Wilms' Tumor Study-3. Ann Surg. 1993 Nov;218(5):654-9.
Ritchey ML, Kelalis PP, Breslow N, Etzioni R, Evans I, Haase GM, D'Angio GJ. Surgical complications after nephrectomy for Wilms' tumor. Surg Gynecol Obstet. 1992 Dec;175(6):507-14.